Evidence map›Paper›PMID 30759239›Full record

ArticlePathogens and disease2019

Temporal proteomic profiling reveals changes that support Burkholderia biofilms.

Mohd M Khan, Supaksorn Chattagul, Bao Q Tran, Jeffrey A Freiberg, Aleksandra Nita-Lazar, Mark E Shirtliff, Rasana W Sermswan, Robert K Ernst, David R Goodlett

Open access · bronzeAbstract read
In one paragraph

Article in Pathogens and disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Understanding bacterial biofilms: From definition to treatment strategies.Frontiers in cellular and infection microbiology · 2023
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Chicken Juice EnhancesFoods (Basel, Switzerland) · 2024
    Article
  6. Unraveling the molecular dynamics ofFuture microbiology · 2024
    Article
  7. Article
  8. How to study biofilms: technological advancements in clinical biofilm research.Frontiers in cellular and infection microbiology · 2023
    Review
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Mohd M KhanUniversity of Maryland School of Medicine, Baltimore, MD 21201, USA.
Supaksorn ChattagulMelioidosis Research Center, Khon Kaen University, Khon Kaen 40002, Thailand.
Bao Q TranDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA.
Jeffrey A FreibergDepartment of Microbial Pathogenesis, University of Maryland School of Dentistry, Baltimore, MD 21201, USA.
Aleksandra Nita-LazarLaboratory of Immune System Biology (LISB), National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD 20814, USA.
Mark E ShirtliffDepartment of Microbial Pathogenesis, University of Maryland School of Dentistry, Baltimore, MD 21201, USA.
Rasana W SermswanMelioidosis Research Center, Khon Kaen University, Khon Kaen 40002, Thailand.
Robert K ErnstDepartment of Microbial Pathogenesis, University of Maryland School of Dentistry, Baltimore, MD 21201, USA.
David R GoodlettDepartment of Microbial Pathogenesis, University of Maryland School of Dentistry, Baltimore, MD 21201, USA.
University of Maryland, Baltimore · USKhon Kaen University · THNational Institute of Allergy and Infectious Diseases · US

Funding

Protein Modifications Involved in Cell SignalingZIAAI001084 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI NITA-LAZAR, ALEKSANDRA · 2009 to 2025
$11.4M
Protection Against Gram-Negative Sepsis Conferred by Lipid A-Based Structural VariantsR01AI123820 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI ERNST, ROBERT K, GOODLETT, DAVID ROBINSON · 2016 to 2019
$1.5M
NIAID NIH HHS R01 AI123820
6 · The paper itself

Abstract

Melioidosis associated with opportunistic pathogen Burkholderia pseudomallei imparts a huge medical burden in Southeast Asia and Australia. At present there is no available human vaccine that protects against B. pseudomallei infection and antibiotic treatments are limited particularly for drug-resistant strains and bacteria in biofilm forms. Biofilm forming bacteria exhibit phenotypic features drastically different to their planktonic states, often exhibiting a diminished response to antimicrobial therapies. Our earlier work on global profiling of bacterial biofilms using transcriptomics and proteomics revealed transcript-decoupled protein abundance in bacterial biofilms. Here we employed reverse phase liquid chromatography tandem mass spectrometry (LC-MS/MS) to deduce temporal proteomic differences in planktonic and biofilm forms of Burkholderia thailandensis, which is weakly surrogate model of pathogenic B. pseudomallei as sharing a key element in genomic similarity. The proteomic analysis of B. thailandensis in biofilm versus planktonic states revealed that proteome changes support biofilm survival through decreased abundance of metabolic proteins while increased abundance of stress-related proteins. Interestingly, the protein abundance including for the transcription protein TEX, outer periplasmic TolB protein, and the exopolyphosphatase reveal adaption in bacterial biofilms that facilitate antibiotic tolerance through a non-specific mechanism. The present proteomics study of B. thailandensis biofilms provides a global snapshot of protein abundance differences and antimicrobial sensitivities in planktonic and sessile bacteria.

Indexed as

BiofilmsProteomeProteomicsAnti-Infective AgentsBacterial ProteinsBurkholderiaChromatography, LiquidComputational BiologyMicrobial Sensitivity TestsTandem Mass SpectrometryAnti-Infective AgentsBacterial ProteinsProteomeantimicrobial tolerancebiofilmsliquid chromatography mass spectrometrymelioidosisproteomics

Identifiers

PMID30759239
PMCPMC6482045
OpenAlexW2914247124

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.